Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

In vivo cation exchange in quantum dots for tumor-specific imaging.

Liu X, Braun GB, Qin M, Ruoslahti E, Sugahara KN.

Nat Commun. 2017 Aug 24;8(1):343. doi: 10.1038/s41467-017-00153-y.

2.

Ratiometric in vivo auditioning of targeted silver nanoparticles.

Toome K, Willmore AA, Paiste P, Tobi A, Sugahara KN, Kirsimäe K, Ruoslahti E, Braun GB, Teesalu T.

Nanoscale. 2017 Jul 20;9(28):10094-10100. doi: 10.1039/c7nr04056c.

3.

Targeting of p32 in peritoneal carcinomatosis with intraperitoneal linTT1 peptide-guided pro-apoptotic nanoparticles.

Hunt H, Simón-Gracia L, Tobi A, Kotamraju VR, Sharma S, Nigul M, Sugahara KN, Ruoslahti E, Teesalu T.

J Control Release. 2017 Aug 28;260:142-153. doi: 10.1016/j.jconrel.2017.06.005. Epub 2017 Jun 8.

4.

Hyaluronan-binding peptide for targeting peritoneal carcinomatosis.

Ikemoto H, Lingasamy P, Anton Willmore AM, Hunt H, Kurm K, Tammik O, Scodeller P, Simón-Gracia L, Kotamraju VR, Lowy AM, Sugahara KN, Teesalu T.

Tumour Biol. 2017 May;39(5):1010428317701628. doi: 10.1177/1010428317701628.

5.

iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.

Simón-Gracia L, Hunt H, Scodeller P, Gaitzsch J, Kotamraju VR, Sugahara KN, Tammik O, Ruoslahti E, Battaglia G, Teesalu T.

Biomaterials. 2016 Oct;104:247-57. doi: 10.1016/j.biomaterials.2016.07.023. Epub 2016 Jul 20.

6.

Tumor-Targeted Multimodal Optical Imaging with Versatile Cadmium-Free Quantum Dots.

Liu X, Braun GB, Zhong H, Hall DJ, Han W, Qin M, Zhao C, Wang M, She ZG, Cao C, Sailor MJ, Stallcup WB, Ruoslahti E, Sugahara KN.

Adv Funct Mater. 2016 Jan 13;26(2):267-276. Epub 2015 Dec 2.

7.

Urokinase-controlled tumor penetrating peptide.

Braun GB, Sugahara KN, Yu OM, Kotamraju VR, Mölder T, Lowy AM, Ruoslahti E, Teesalu T.

J Control Release. 2016 Jun 28;232:188-95. doi: 10.1016/j.jconrel.2016.04.027. Epub 2016 Apr 19.

8.

New p32/gC1qR Ligands for Targeted Tumor Drug Delivery.

Paasonen L, Sharma S, Braun GB, Kotamraju VR, Chung TD, She ZG, Sugahara KN, Yliperttula M, Wu B, Pellecchia M, Ruoslahti E, Teesalu T.

Chembiochem. 2016 Apr 1;17(7):570-5. doi: 10.1002/cbic.201500564. Epub 2016 Feb 19.

9.

Targeted silver nanoparticles for ratiometric cell phenotyping.

Willmore AM, Simón-Gracia L, Toome K, Paiste P, Kotamraju VR, Mölder T, Sugahara KN, Ruoslahti E, Braun GB, Teesalu T.

Nanoscale. 2016 Apr 28;8(17):9096-101. doi: 10.1039/c5nr07928d.

10.

A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis.

Sugahara KN, Scodeller P, Braun GB, de Mendoza TH, Yamazaki CM, Kluger MD, Kitayama J, Alvarez E, Howell SB, Teesalu T, Ruoslahti E, Lowy AM.

J Control Release. 2015 Aug 28;212:59-69. doi: 10.1016/j.jconrel.2015.06.009. Epub 2015 Jun 11.

11.

Nanoparticles coated with the tumor-penetrating peptide iRGD reduce experimental breast cancer metastasis in the brain.

Hamilton AM, Aidoudi-Ahmed S, Sharma S, Kotamraju VR, Foster PJ, Sugahara KN, Ruoslahti E, Rutt BK.

J Mol Med (Berl). 2015 Sep;93(9):991-1001. doi: 10.1007/s00109-015-1279-x. Epub 2015 Apr 14.

12.

Tumor-penetrating iRGD peptide inhibits metastasis.

Sugahara KN, Braun GB, de Mendoza TH, Kotamraju VR, French RP, Lowy AM, Teesalu T, Ruoslahti E.

Mol Cancer Ther. 2015 Jan;14(1):120-8. doi: 10.1158/1535-7163.MCT-14-0366. Epub 2014 Nov 12.

13.

An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability.

Pang HB, Braun GB, Friman T, Aza-Blanc P, Ruidiaz ME, Sugahara KN, Teesalu T, Ruoslahti E.

Nat Commun. 2014 Oct 3;5:4904. doi: 10.1038/ncomms5904.

14.

Etchable plasmonic nanoparticle probes to image and quantify cellular internalization.

Braun GB, Friman T, Pang HB, Pallaoro A, Hurtado de Mendoza T, Willmore AM, Kotamraju VR, Mann AP, She ZG, Sugahara KN, Reich NO, Teesalu T, Ruoslahti E.

Nat Mater. 2014 Sep;13(9):904-11. doi: 10.1038/nmat3982. Epub 2014 Jun 8.

15.

A free cysteine prolongs the half-life of a homing peptide and improves its tumor-penetrating activity.

Pang HB, Braun GB, She ZG, Kotamraju VR, Sugahara KN, Teesalu T, Ruoslahti E.

J Control Release. 2014 Feb 10;175:48-53. doi: 10.1016/j.jconrel.2013.12.006. Epub 2013 Dec 15.

16.

Tumor-penetrating peptides.

Teesalu T, Sugahara KN, Ruoslahti E.

Front Oncol. 2013 Aug 27;3:216. doi: 10.3389/fonc.2013.00216. eCollection 2013.

17.

Proapoptotic peptide-mediated cancer therapy targeted to cell surface p32.

Agemy L, Kotamraju VR, Friedmann-Morvinski D, Sharma S, Sugahara KN, Ruoslahti E.

Mol Ther. 2013 Dec;21(12):2195-204. doi: 10.1038/mt.2013.191. Epub 2013 Aug 20. Erratum in: Mol Ther. 2014 Nov;22(11):2013.

18.

Proteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies.

Sánchez-Martín D, Martínez-Torrecuadrada J, Teesalu T, Sugahara KN, Alvarez-Cienfuegos A, Ximénez-Embún P, Fernández-Periáñez R, Martín MT, Molina-Privado I, Ruppen-Cañás I, Blanco-Toribio A, Cañamero M, Cuesta AM, Compte M, Kremer L, Bellas C, Alonso-Camino V, Guijarro-Muñoz I, Sanz L, Ruoslahti E, Alvarez-Vallina L.

Proc Natl Acad Sci U S A. 2013 Aug 20;110(34):13791-6. doi: 10.1073/pnas.1300013110. Epub 2013 Aug 5.

19.

Sequence dependence of C-end rule peptides in binding and activation of neuropilin-1 receptor.

Zanuy D, Kotla R, Nussinov R, Teesalu T, Sugahara KN, Alemán C, Haspel N.

J Struct Biol. 2013 May;182(2):78-86. doi: 10.1016/j.jsb.2013.02.006. Epub 2013 Feb 24.

20.

Application of a proapoptotic peptide to intratumorally spreading cancer therapy.

Chen R, Braun GB, Luo X, Sugahara KN, Teesalu T, Ruoslahti E.

Cancer Res. 2013 Feb 15;73(4):1352-61. doi: 10.1158/0008-5472.CAN-12-1979. Epub 2012 Dec 17.

21.

De novo design of a tumor-penetrating peptide.

Alberici L, Roth L, Sugahara KN, Agemy L, Kotamraju VR, Teesalu T, Bordignon C, Traversari C, Rizzardi GP, Ruoslahti E.

Cancer Res. 2013 Jan 15;73(2):804-12. doi: 10.1158/0008-5472.CAN-12-1668. Epub 2012 Nov 14.

22.

Mapping of vascular ZIP codes by phage display.

Teesalu T, Sugahara KN, Ruoslahti E.

Methods Enzymol. 2012;503:35-56. doi: 10.1016/B978-0-12-396962-0.00002-1. Review.

PMID:
22230564
23.

Transtumoral targeting enabled by a novel neuropilin-binding peptide.

Roth L, Agemy L, Kotamraju VR, Braun G, Teesalu T, Sugahara KN, Hamzah J, Ruoslahti E.

Oncogene. 2012 Aug 16;31(33):3754-63. doi: 10.1038/onc.2011.537. Epub 2011 Dec 19.

PMID:
22179825
24.

Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma.

Agemy L, Friedmann-Morvinski D, Kotamraju VR, Roth L, Sugahara KN, Girard OM, Mattrey RF, Verma IM, Ruoslahti E.

Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17450-5. doi: 10.1073/pnas.1114518108. Epub 2011 Oct 3. Erratum in: Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):11906.

25.

Selection of phage-displayed peptides on live adherent cells in microfluidic channels.

Wang J, Liu Y, Teesalu T, Sugahara KN, Kotamrajua VR, Adams JD, Ferguson BS, Gong Q, Oh SS, Csordas AT, Cho M, Ruoslahti E, Xiao Y, Soh HT.

Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):6909-14. doi: 10.1073/pnas.1014753108. Epub 2011 Apr 12.

26.

Optimization of iron oxide nanoparticle detection using ultrashort echo time pulse sequences: comparison of T1, T2*, and synergistic T1- T2* contrast mechanisms.

Girard OM, Du J, Agemy L, Sugahara KN, Kotamraju VR, Ruoslahti E, Bydder GM, Mattrey RF.

Magn Reson Med. 2011 Jun;65(6):1649-60. doi: 10.1002/mrm.22755. Epub 2011 Feb 8.

27.

Nanoparticle-induced vascular blockade in human prostate cancer.

Agemy L, Sugahara KN, Kotamraju VR, Gujraty K, Girard OM, Kono Y, Mattrey RF, Park JH, Sailor MJ, Jimenez AI, Cativiela C, Zanuy D, Sayago FJ, Aleman C, Nussinov R, Ruoslahti E.

Blood. 2010 Oct 14;116(15):2847-56. doi: 10.1182/blood-2010-03-274258. Epub 2010 Jun 29.

28.

Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.

Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, Ruoslahti E.

Science. 2010 May 21;328(5981):1031-5. doi: 10.1126/science.1183057. Epub 2010 Apr 8.

29.

Tissue-penetrating delivery of compounds and nanoparticles into tumors.

Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, Hanahan D, Mattrey RF, Ruoslahti E.

Cancer Cell. 2009 Dec 8;16(6):510-20. doi: 10.1016/j.ccr.2009.10.013.

30.

C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration.

Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E.

Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16157-62. doi: 10.1073/pnas.0908201106. Epub 2009 Sep 2.

31.

Involvement of chondroitin sulfate E in the liver tumor focal formation of murine osteosarcoma cells.

Basappa, Murugan S, Sugahara KN, Lee CM, ten Dam GB, van Kuppevelt TH, Miyasaka M, Yamada S, Sugahara K.

Glycobiology. 2009 Jul;19(7):735-42. doi: 10.1093/glycob/cwp041. Epub 2009 Mar 17.

32.

Cell surface nucleolin antagonist causes endothelial cell apoptosis and normalization of tumor vasculature.

Fogal V, Sugahara KN, Ruoslahti E, Christian S.

Angiogenesis. 2009;12(1):91-100. doi: 10.1007/s10456-009-9137-5. Epub 2009 Feb 19.

PMID:
19225898
33.

Chondroitin sulfate E fragments enhance CD44 cleavage and CD44-dependent motility in tumor cells.

Sugahara KN, Hirata T, Tanaka T, Ogino S, Takeda M, Terasawa H, Shimada I, Tamura J, ten Dam GB, van Kuppevelt TH, Miyasaka M.

Cancer Res. 2008 Sep 1;68(17):7191-9. doi: 10.1158/0008-5472.CAN-07-6198.

34.

Ligand-induced structural changes of the CD44 hyaluronan-binding domain revealed by NMR.

Takeda M, Ogino S, Umemoto R, Sakakura M, Kajiwara M, Sugahara KN, Hayasaka H, Miyasaka M, Terasawa H, Shimada I.

J Biol Chem. 2006 Dec 29;281(52):40089-95. Epub 2006 Nov 2.

35.

Hyaluronan fragments: an information-rich system.

Stern R, Asari AA, Sugahara KN.

Eur J Cell Biol. 2006 Aug;85(8):699-715. Epub 2006 Jul 5. Review.

PMID:
16822580
36.

Tumor cells enhance their own CD44 cleavage and motility by generating hyaluronan fragments.

Sugahara KN, Hirata T, Hayasaka H, Stern R, Murai T, Miyasaka M.

J Biol Chem. 2006 Mar 3;281(9):5861-8. Epub 2005 Dec 29.

37.

Engagement of CD44 promotes Rac activation and CD44 cleavage during tumor cell migration.

Murai T, Miyazaki Y, Nishinakamura H, Sugahara KN, Miyauchi T, Sako Y, Yanagida T, Miyasaka M.

J Biol Chem. 2004 Feb 6;279(6):4541-50. Epub 2003 Nov 17.

38.

Hyaluronan oligosaccharides induce CD44 cleavage and promote cell migration in CD44-expressing tumor cells.

Sugahara KN, Murai T, Nishinakamura H, Kawashima H, Saya H, Miyasaka M.

J Biol Chem. 2003 Aug 22;278(34):32259-65. Epub 2003 Jun 11.

Supplemental Content

Loading ...
Support Center